GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PRQR
ProQR is a biotech company specializing in RNA therapy for rare genetic diseases. Its stock price reflects the high volatility and risks inherent in the sector. The chart is a history of ups and downs related to clinical trial results.
Share prices of companies in the market segment - Dna
ProQR Therapeutics is a Dutch biotech company developing RNA-based therapies for the treatment of rare genetic diseases, particularly eye diseases. We've categorized it as a "DNA" company, and the chart below shows how the market views the prospects for this breakthrough in genetic medicine.
Broad Market Index - GURU.Markets
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for the treatment of rare genetic diseases, particularly eye diseases. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market trend.
Change in the price of a company, segment, and market as a whole per day
PRQR - Daily change in the company's share price PRQR
ProQR, an RNA therapeutics company, experiences daily fluctuations reflecting the inherent volatility of biotech. change_co measures the company's reaction to research data and regulatory decisions. This metric is important for analyzing high-risk pharmaceutical companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
ProQR Therapeutics N.V. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with PRQR, which focuses on treating rare genetic diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
ProQR is a biopharmaceutical company specializing in RNA-based drugs for the treatment of genetic diseases. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with ProQR's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PRQR
ProQR Therapeutics N.V.'s year-over-year performance is a story about developing RNA-based therapies for rare genetic eye diseases. Its 12-month market cap is critically dependent on clinical trial data. Any success can be a breakthrough, but setbacks in this complex field lead to sharp declines, which is typical for biotech.
Annual dynamics of market capitalization of the market segment - Dna
ProQR Therapeutics N.V. is a biotech company developing RNA therapies for the treatment of rare genetic diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ProQR Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PRQR
The price of ProQR, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of its RNA-editing platform and the progress of clinical trials of drugs for the treatment of rare genetic diseases.
Monthly dynamics of market capitalization of the market segment - Dna
ProQR Therapeutics is developing RNA therapies to treat rare genetic diseases. This is one of the most cutting-edge areas in biotechnology. The chart below shows how investor confidence in the potential of RNA medicine has fluctuated, reflecting the overall sentiment in this segment, where a single successful or unsuccessful trial result can change everything.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for the treatment of rare genetic diseases. Its stock price is dependent solely on clinical trial results. It is a high-risk investment in cutting-edge science that is not correlated with the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PRQR
Shares of ProQR Therapeutics, a Dutch company developing RNA therapy for rare genetic diseases, are extremely volatile. Weekly price movements depend entirely on clinical trial results. The chart below illustrates how hopes and disappointments in this complex field of medicine drive sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Dna
How unique is ProQR Therapeutics' performance in the biotech sector? This chart compares the weekly price movements of this RNA therapy company with the overall trend. This helps us understand whether its sharp movements are a unique reaction to news in this cutting-edge field or reflect broader sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ProQR Therapeutics is developing RNA therapy for rare genetic diseases. This chart shows how out of sync its weekly performance is with the market. Its stock moves are driven by clinical trial news and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
PRQR - Market capitalization of the company PRQR
ProQR Therapeutics N.V.'s market cap is a bet on its RNA therapy platform for treating rare genetic eye diseases. This Dutch biotech's valuation is extremely sensitive to clinical trial results. The chart clearly shows how news from the lab can dramatically change its value.
PRQR - Share of the company's market capitalization PRQR within the market segment - Dna
ProQR Therapeutics N.V. is a biotech company whose market share is based on its RNA-based therapeutic platform for treating rare genetic diseases. Its market capitalization reflects its emerging strategy and the potential of its technologies.
Market capitalization of the market segment - Dna
Here's a chart of the total market capitalization of biotech companies developing RNA therapies for rare diseases. ProQR Therapeutics is one of the pioneers in this field. The chart shows how the market values this cutting-edge, yet high-risk, technology, which could treat genetic diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with rare genetic eye diseases. ProQR Therapeutics' market cap is a bet on its RNA therapy platform. The line shows how cutting-edge science aimed at restoring vision is generating enormous potential value in global medicine.
Book value capitalization of the company, segment and market as a whole
PRQR - Book value capitalization of the company PRQR
ProQR Therapeutics' book value represents its scientific capital. The chart below reflects the valuation of its RNA therapy platform, which targets rare genetic eye diseases. The pipeline's growth signals clinical trial success, which is the primary tangible embodiment of this biotech company's value.
PRQR - Share of the company's book capitalization PRQR within the market segment - Dna
For ProQR, which is developing RNA therapy for genetic eye diseases, its tangible assets include cutting-edge laboratories and scientific equipment. The chart shows its share of this unique scientific infrastructure, which provides the physical foundation for the creation of breakthrough treatments.
Market segment balance sheet capitalization - Dna
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, ProQR, which is developing RNA therapies for rare diseases, looks like a "lightweight." Its value lies in its unique scientific platform and patents, not its manufacturing capacity.
Book value of all companies included in the broad market index - GURU.Markets
ProQR Therapeutics develops RNA therapeutics for the treatment of rare genetic diseases. The company's assets are not its manufacturing plants, but rather its scientific platform and development portfolio. The company's balance sheet is the value of its technology, which enables RNA editing to correct genetic defects in real organisms.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PRQR
ProQR's balance sheet consists of its cash and its scientific platform. Its market capitalization, close to its cash value, suggests that investors have written off its previous developments and are valuing the company almost as a "piggy bank" with a small margin of success for its new strategy.
Market to book capitalization ratio in a market segment - Dna
ProQR Therapeutics is a biotech company developing RNA therapy for the treatment of rare genetic eye diseases. Its value lies in its scientific platform. The chart shows a speculative estimate of its potential, which depends on the results of clinical trials.
Market to book capitalization ratio for the market as a whole
ProQR Therapeutics is a biotech company specializing in developing RNA-based therapies for rare genetic eye diseases. Its value lies in its scientific platform and the potential of its drug candidates. This chart illustrates why investors are willing to pay a premium for breakthrough approaches to treating rare diseases.
Debts of the company, segment and market as a whole
PRQR - Company debts PRQR
ProQR Therapeutics, a company developing RNA therapies to treat genetic eye diseases, uses debt to finance its research. This chart shows how the company raises capital to conduct complex and expensive clinical trials. In this field, debt is an investment in hope for patients with rare diseases.
Market segment debts - Dna
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for the treatment of rare genetic eye diseases. This is a cutting-edge scientific field that requires long-term funding. This chart shows how the clinical-stage company manages its capital to advance its innovative, yet risky, developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PRQR
ProQR Therapeutics is developing RNA therapy for rare genetic diseases. This chart shows its reliance on debt to fund its cutting-edge, yet expensive, research. For a clinical-stage biotech company, high debt is a huge risk, entirely dependent on the success of its research.
Market segment debt to market segment book capitalization - Dna
ProQR Therapeutics is developing RNA therapy for rare genetic eye diseases. This is a cutting-edge, but very expensive, area of research. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
ProQR Therapeutics (PRQR) is a biotech company developing RNA therapies for rare genetic eye diseases. This chart shows the overall debt burden of the economy. It provides an excellent backdrop for understanding why companies like ProQR are solely shareholder-funded during the clinical development stage, avoiding debt risk.
P/E of the company, segment and market as a whole
P/E - PRQR
For ProQR Therapeutics, a company developing RNA therapy for rare genetic eye diseases, this chart is a measure of hope. There is no P/E ratio. The valuation depends entirely on the results of clinical trials. Trial failures could lead to a sharp decline, while success could lead to explosive growth.
P/E of the market segment - Dna
This chart illustrates the average P/E ratio for biotech companies. For ProQR, which works in RNA therapy for rare diseases, it serves as a backdrop. It shows the overall level of investor faith in this cutting-edge but risky field of science, providing context for evaluating its specific developments.
P/E of the market as a whole
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for the treatment of rare genetic diseases, particularly those associated with vision loss. The company is a pioneer in this field. This risk appetite chart helps understand how investors value companies at the forefront of genetic medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PRQR
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for the treatment of rare genetic eye diseases. This graph reflects the expectations for its innovative approach to treating hereditary blindness. The assessment is entirely dependent on the results of clinical trials and the potential of its drugs to restore vision in patients.
%20P%2FE%20PRQR&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PRQR&v=1772531048128 "Chart of the company's future (projected) P/E PRQR")
Future (projected) P/E of the market segment - Dna
ProQR Therapeutics is developing RNA-based therapies for the treatment of rare genetic eye diseases. This chart reflects the company's long-term profitability expectations. It demonstrates how highly the market values their scientific platform and the potential to create first-of-a-kind vision-restoring drugs for patients.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772531048237 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
ProQR Therapeutics is a Dutch biotech company developing RNA therapy for the treatment of rare genetic eye diseases. Its future depends on the success of clinical trials. This market expectations chart reflects investor willingness to fund breakthrough, yet risky, gene therapy projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772531048282 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PRQR
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for the treatment of rare genetic diseases, primarily vision-related. Its financial results reflect the costs of clinical trials in the hopes of developing drugs that correct genetic defects.
Profit of companies in the market segment - Dna
ProQR Therapeutics is developing RNA-based therapies for rare genetic eye diseases. The company is at the forefront of science, which entails high-risk clinical trials. This chart for the biotech sector illustrates how a focus on orphan diseases and cutting-edge technologies is shaping its future profitability, despite current R&D expenditures.
Overall market profit
ProQR Therapeutics is a biotech company developing RNA therapy for rare genetic eye diseases. Its future depends solely on the results of clinical trials. This is a high-risk venture, where value is created by scientific breakthroughs rather than by the macroeconomic trends visible in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PRQR
ProQR Therapeutics specializes in developing RNA-based therapies for the treatment of rare genetic eye diseases. This schedule reflects expectations, which are entirely dependent on the results of clinical trials. Success in restoring vision in patients with inherited retinal diseases could dramatically change the prognosis.
%20profit%20of%20the%20company%20PRQR&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PRQR&v=1772531048485 "Graph of future (projected) profit of the company PRQR")
Future (predicted) profit of companies in the market segment - Dna
ProQR Therapeutics is a Dutch biotech company developing RNA therapeutics for the treatment of rare genetic eye diseases. This chart shows the revenue forecast for the entire DNA and RNA therapeutics industry. It reflects expectations for breakthroughs in the treatment of inherited diseases. This background is important for assessing the scientific potential and prospects of the ProQR platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772531048500 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
ProQR Therapeutics is a Dutch biotech company developing RNA therapy for the treatment of rare genetic eye diseases. Its future depends on the success of clinical trials. The overall economic climate, reflected in this chart, influences the company through the availability of funding for long-term and risky research projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772531048576 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PRQR
ProQR Therapeutics is a Dutch biotech developing RNA therapeutics for the treatment of rare genetic eye diseases. This chart shows how investors are valuing its scientific platform after a series of clinical trial failures, placing their bets on the remaining programs and the potential of its technology.
P/S market segment - Dna
ProQR Therapeutics is a Dutch biotech company specializing in the development of RNA-based therapeutics for the treatment of rare genetic diseases, particularly inherited retinal diseases that lead to blindness. This chart shows the average valuation in the sector, helping to understand the market premium placed on ProQR's innovative scientific platform.
P/S of the market as a whole
ProQR Therapeutics is a Dutch biotech developing RNA therapy for rare genetic eye diseases. This cutting-edge technology aims to restore vision. This market valuation chart helps understand the premium investors are paying for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PRQR
ProQR Therapeutics is a biotech company developing RNA therapies for the treatment of rare genetic diseases. Without revenue, it is valued based on future potential. This chart reflects investor expectations for the success of its clinical programs.
%20P%2FS%20PRQR&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PRQR&v=1772531048841 "The graph of the company's future (projected) P/S PRQR")
Future (projected) P/S of the market segment - Dna
ProQR Therapeutics is developing RNA therapeutics for the treatment of rare genetic diseases. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. The valuation reflects investor expectations for the success of its platform and clinical programs, particularly in ophthalmology.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772531048850 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
ProQR Therapeutics is developing an RNA therapy for rare genetic eye diseases. Its price is a bet on future scientific success. Overall market optimism, reflected in this chart, is critical for the company, as it provides access to the capital needed to conduct lengthy and expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772531048867 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PRQR
ProQR Therapeutics is a biotech company developing RNA-based therapies for the treatment of rare genetic eye diseases. Currently in the clinical stage, its revenue comes from partnerships with major pharmaceutical companies. The chart reflects funding supporting its cutting-edge ophthalmology research.
Sales of companies in the market segment - Dna
ProQR Therapeutics is a Dutch biotech company specializing in the development of RNA-based therapies for the treatment of rare genetic diseases. Its platforms enable the correction of genetic defects at the RNA level. Currently, revenue is generated from partnerships. This chart demonstrates the potential of RNA technologies, which are opening new horizons in the treatment of inherited diseases.
Overall market sales
ProQR Therapeutics is developing RNA therapy for the treatment of rare genetic eye diseases. The company's future depends on the success of its clinical programs. This timeline is important indirectly: the overall economic situation affects the availability of capital needed to fund lengthy and expensive gene therapy research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PRQR
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for the treatment of rare genetic eye diseases. This chart reflects analyst expectations for the success of its clinical programs and the commercial potential of its innovative treatments for hereditary blindness.
%20sales%20of%20the%20company%20PRQR&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PRQR&v=1772531049031 "Schedule of future (projected) sales of the company PRQR")
Future (projected) sales of companies in the market segment - Dna
ProQR Therapeutics is developing RNA therapeutics for the treatment of rare genetic diseases, particularly those related to vision. This chart shows the overall outlook for the DNA and RNA therapeutics sector. It allows one to assess the potential of the company's platform and how clinical trial results may impact its future in this complex field of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772531049098 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
ProQR Therapeutics N.V. is developing RNA therapeutics for the treatment of rare genetic diseases. This graph, reflecting the investment climate in biotech, is critically important. Developing such advanced treatments requires significant capital, and the availability of funding, linked to the overall economic situation, is a key factor for ProQR.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772531049140 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PRQR
ProQR Therapeutics is developing RNA therapeutics for the treatment of rare genetic diseases, particularly those associated with vision loss. The company's business is at the forefront of science and requires significant investment in clinical trials. This chart illustrates the "cost of innovation"—the costs required to create potentially revolutionary drugs.
Market segment marginality - Dna
ProQR Therapeutics is a biotech company developing RNA therapies for the treatment of rare genetic eye diseases. Their platform is aimed at correcting genetic defects. This chart reflects their intensive investment in this cutting-edge science, which has the potential to save patients' sight and deliver high profitability in the future.
Market marginality as a whole
ProQR Therapeutics is a Dutch biotech company developing RNA therapy for rare genetic eye diseases. The overall profitability picture is irrelevant for them. Their future depends entirely on the results of clinical trials. This is a high-risk bet on an innovative technology that could save patients' sight.
Employees in the company, segment and market as a whole
Number of employees in the company PRQR
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for rare genetic diseases. This chart shows the team's scientific staff. The staffing dynamics reflect the ups and downs associated with clinical trial results, which is typical for this sector.
Share of the company's employees PRQR within the market segment - Dna
ProQR Therapeutics is developing RNA therapeutics for the treatment of rare genetic diseases. This chart shows the percentage of leading scientists in RNA biology and genetics that the company attracts. This demonstrates its focus on cutting-edge technologies and its team working to develop drugs that can correct genetic defects at the RNA level.
Number of employees in the market segment - Dna
ProQR Therapeutics is a Dutch biotechnology company specializing in the development of RNA-based therapies for the treatment of rare genetic eye diseases. This chart shows employment in the biotechnology sector. The employee growth reflects the successes and failures of clinical trials, which are crucial for the company's future in this innovative field.
Number of employees in the market as a whole
ProQR Therapeutics N.V. is a Dutch biotech company developing RNA therapies for the treatment of rare genetic diseases, primarily vision-related. This is a cutting-edge field of medicine. This graph, which shows the overall labor market, shows companies like ProQR creating unique jobs for scientists working on treatments for diseases previously considered incurable.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PRQR (PRQR)
ProQR Therapeutics N.V. is a Dutch biotech company developing RNA therapies for the treatment of rare genetic diseases. Its value lies in the potential of its scientific platform. This chart clearly demonstrates a business driven by intellectual capital, with an extremely high market capitalization per employee. Investors are betting on their scientific breakthroughs.
%20of%20the%20company%20PRQR%20(PRQR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PRQR-PRQR&v=1772531049340 "Chart of market capitalization per employee (in thousands of dollars) of the company PRQR (PRQR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
ProQR Therapeutics is developing RNA therapy for rare genetic eye diseases. This is a cutting-edge and highly focused area of biotechnology. The chart shows the market's high valuation of its scientific platform. The per-employee price reflects investors' hopes that its team will be able to create a vision-restoring drug.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772531049345 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
ProQR Therapeutics is a Dutch biotech company developing RNA-based therapies for the treatment of rare genetic eye diseases. This chart shows a high market value per employee, reflecting investors' faith in the potential of their scientific platform to save patients' sight.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772531049374 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PRQR (PRQR)
ProQR Therapeutics (PRQR) is a Dutch biotech company developing RNA therapies for the treatment of rare genetic eye diseases. This is cutting-edge R&D. This chart shows the "cost" of this highly specialized research—the negative profit (expense) per scientist.
%20Chart%20PRQR%20(PRQR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PRQR-PRQR&v=1772531049430 "Company Profit Per Employee (in thousands of dollars) Chart PRQR (PRQR)")
Profit per employee (in thousands of dollars) in the market segment - Dna
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for the treatment of rare genetic diseases associated with vision loss. Their core business is R&D. This chart shows the benchmark for biotech staff efficiency. It's important for assessing how effectively ProQR's scientific team is using its drug discovery platform.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772531049435 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
ProQR Therapeutics is a Dutch biotech company specializing in RNA therapies for rare genetic eye diseases. This is a highly specialized and complex area of R&D. The chart shows the R&D investment (negative return) per scientist in an effort to develop treatments for patients who currently have no treatment options.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772531049453 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PRQR (PRQR)
ProQR Therapeutics is a biotech company developing RNA-based therapies for rare genetic eye diseases. This chart reflects its focus on research. No revenue per employee is normal for a clinical-stage company whose primary goal is to prove the efficacy of its innovative drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PRQR-PRQR&v=1772531049492 "Sales chart per company employee PRQR (PRQR)")
Sales per employee in the market segment - Dna
ProQR Therapeutics (PRQR) is a Dutch biotech company specializing in RNA-based therapies for rare genetic eye diseases. This chart shows the revenue (from partnerships) generated by each employee (scientist). It's an indicator of the productivity of their R&D platform in the ophthalmology niche.
Sales per employee for the market as a whole
ProQR Therapeutics (PRQR) is a clinical-stage biotech company specializing in RNA-based therapies for rare genetic eye diseases. It is an R&D company with no stable revenue. This graph (close to zero) reflects its investment in science: its scientists are working on developing breakthrough treatments for blindness, and investors are anticipating future returns.
Short shares by company, segment and market as a whole
Shares shorted by company PRQR (PRQR)
ProQR Therapeutics is a biotech company developing RNA therapies for rare genetic eye diseases. This chart shows bearish bets. The shorts are driven by the company's failure in key clinical trials, casting doubt on its entire scientific platform and future.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PRQR-PRQR&v=1772531049590 "Short Shares Chart for the Company PRQR (PRQR)")
Shares shorted by market segment - Dna
ProQR Therapeutics (PRQR) is a biotech company developing RNA therapies to treat rare genetic eye diseases that lead to blindness. This chart is a barometer of sentiment across the biotech industry. If investors are shorting the sector, they are unsure of the success of risky R&D, especially after the company's past failures in trials.
Shares shorted by the overall market
ProQR Therapeutics is a clinical-stage biotech company specializing in RNA therapeutics. Its valuation is based on future scientific advances. When the market is gripped by fear (high values on this chart), investors avoid any risk. Financing speculative, revenue-deficient biotechs like ProQR becomes virtually impossible.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PRQR (PRQR)
ProQR Therapeutics develops RNA therapies for rare genetic diseases. The stock is highly speculative and dependent on R&D. This chart can soar above 70 on positive trial data. Oversold territory (<30) often reflects setbacks, delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PRQR-PRQR&v=1772531049634 "RSI 14 indicator chart for the company's stock PRQR (PRQR)")
RSI 14 Market Segment - Dna
ProQR Therapeutics is a Dutch biotech company developing RNA therapies for the treatment of rare genetic diseases that cause blindness. This sector is highly dependent on clinical trial data. This chart measures the collective momentum in the gene and RNA therapy sector. It helps distinguish the reaction to PRQR's clinical data from the general "emotional" wave across the industry.
RSI 14 for the overall market
ProQR Therapeutics (PRQR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PRQR (PRQR)
ProQR Therapeutics is a Dutch biotech company using RNA-based therapeutics (Axiomer) to treat rare genetic diseases. This chart shows the speculative average price target from analysts based on their belief in this R&D platform, particularly in liver and CNS diseases.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PRQR-PRQR&v=1772531049706 "A chart showing analyst consensus forecasts for the expected stock price. PRQR (PRQR)")
The difference between the consensus estimate and the actual stock price PRQR (PRQR)
ProQR (PRQR) is a Dutch biotech focused on RNA therapy for rare genetic eye diseases (blindness). This is a high-risk R&D bet. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the company's scientific platform (Axiomer) and its clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PRQR-PRQR&v=1772531049710 "A chart showing the difference between the consensus forecast and the actual stock price. PRQR (PRQR)")
Analyst consensus forecast for stock prices by market segment - Dna
ProQR is a Dutch biotech company developing RNA therapies for the treatment of rare genetic diseases that cause blindness. This chart shows analysts' overall expectations for the DNA (and RNA) technology sector. It reflects whether experts believe this complex R&D platform in ophthalmology will be commercially successful.
Analysts' consensus forecast for the overall market share price
ProQR is a biotech at the cutting edge of science (RNA editing for eye diseases). This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = risk aversion, and capital for R&D (like PRQR's) dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PRQR
ProQR (PRQR) is a clinical-stage biotech focused on rare genetic eye diseases. Their signature product is an RNA therapy that repairs defective genes. This chart represents a pure R&D bet. Its valuation reflects the market's faith in their scientific platform and the (highly risky) data from their blindness treatment clinical trials.
AKIMA Market Segment Index - Dna
ProQR Therapeutics is a Dutch company specializing in RNA therapies for the treatment of rare genetic diseases, primarily vision-related. This chart shows the average index for the DNA technologies segment. It allows investors to assess how ProQR, at the forefront of science, is performing relative to the sector average.
The AKIM Index for the overall market
ProQR Therapeutics is a biotech company specializing in RNA editing (Axiomer technology) to treat genetic diseases. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this early-stage research platform and partnerships with pharma.
